Senseonics Announces FDA Review for 180-day CGM Nearing Completion; Alnylam and Novartis Announce Collaboration for Liver Failure

Two cardiometabolic-related news items have recently been observed: Senseonics announced updates to its business, including an anticipated PMA supplement approval for its Eversense 180-day CGM “in the coming weeks”; and Alnylam and Novartis announced an exclusive three-year research collaboration to develop an siRNA-based targeted therapy for end-stage liver diseases. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.